Compare ATRA & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRA | MYO |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.6M | 36.9M |
| IPO Year | 2014 | 2017 |
| Metric | ATRA | MYO |
|---|---|---|
| Price | $4.59 | $0.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $7.67 |
| AVG Volume (30 Days) | 429.8K | ★ 504.8K |
| Earning Date | 03-06-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.97 | N/A |
| Revenue | ★ $151,930,000.00 | $41,643,203.00 |
| Revenue This Year | N/A | $24.07 |
| Revenue Next Year | N/A | $17.48 |
| P/E Ratio | $2.46 | ★ N/A |
| Revenue Growth | 51.27 | ★ 65.00 |
| 52 Week Low | $4.20 | $0.71 |
| 52 Week High | $19.15 | $6.39 |
| Indicator | ATRA | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 29.41 | 37.31 |
| Support Level | $4.50 | $0.76 |
| Resistance Level | $5.11 | $0.85 |
| Average True Range (ATR) | 0.38 | 0.07 |
| MACD | 0.34 | -0.01 |
| Stochastic Oscillator | 6.61 | 14.97 |
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).